A 58-year-old man with a 10-year history of type 2 diabetes mellitus presents to the nephrology clinic. His serum creatinine is 2.8 mg/dL, eGFR is 22 mL/min/1.73m², and urine albumin-to-creatinine ratio (UACR) is 450 mg/g. Blood pressure is 148/92 mmHg. He is already on metformin, lisinopril 10 mg daily, and atorvastatin. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has CKD stage 3b (eGFR 22 mL/min/1.73m²) secondary to diabetic nephropathy, evidenced by significant albuminuria (UACR 450 mg/g) and progressive renal dysfunction. He is on a single RAAS inhibitor (lisinopril) with suboptimal blood pressure control. ## Next Step Rationale **Key Point:** In CKD with diabetic nephropathy and albuminuria, the priority is aggressive RAAS blockade optimization and addition of a non-steroidal mineralocorticoid receptor antagonist (MRA) such as finerenone, which has proven cardiovascular and renal protective benefits independent of blood pressure reduction. **High-Yield:** Finerenone (a selective, non-steroidal MRA) is now a cornerstone therapy in CKD with diabetes. It reduces albuminuria, slows eGFR decline, and reduces cardiovascular events. Nephrologist referral at eGFR <30 mL/min/1.73m² is standard of care for: - Optimization of RAAS blockade (consider adding an ARB if ACE-I alone, or switching to combination therapy) - Introduction of finerenone - Preparation for renal replacement therapy if progression continues - Mineral-bone disorder management **Clinical Pearl:** At eGFR 22 mL/min/1.73m², the patient is not yet at dialysis threshold (typically initiated at eGFR <15 or with uremic symptoms). However, proactive nephrology involvement allows time for vascular access planning, education, and optimization of medical therapy. **Warning:** Do NOT discontinue metformin at eGFR 22 mL/min/1.73m² — the 2023 KDIGO guidelines permit metformin use down to eGFR 15 mL/min/1.73m² with caution and dose adjustment. Insulin is not the first-line next step. ## Management Hierarchy | Step | Intervention | Rationale | |------|--------------|----------| | 1 | Optimize RAAS blockade (ACE-I/ARB) | First-line for CKD with albuminuria | | 2 | Add finerenone | Proven renal and CV protection in CKD-DM | | 3 | Target BP <120/80 mmHg | Slows progression (SPRINT trial principles) | | 4 | Nephrologist co-management | Comprehensive CKD care and RRT planning | | 5 | Dialysis preparation | Only when eGFR <15 or symptomatic | [cite:KDIGO 2022 CKD Management Guidelines]